Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nasdaq100 ETF (QQQ) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Nasdaq100 ETFTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Nasdaq100 ETF vs Regeneron Pharmaceuticals Inc — how do they compare? Nasdaq100 ETF trades at $715.35, while Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Nasdaq100 ETF pays none. Which is the better fit depends on your goals.

QQQREGN
52-Week High
$746.16$852.03
52-Week Low
$558.34$555.51
Market Cap
$83.43B
Sector
Health
Enterprise Value
$78.14B
Dividend Yield
0.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nasdaq100 ETF

QQQ trades at $718.36, showing minimal daily movement with a slight decline of 0.08%. Technical indicators signal a bullish trend with strong moving average support, while oscillators remain neutral. The ETF maintains its position as a leading Nasdaq-100 tracker, though financial ratios are not applicable for this index fund structure. Recent news highlights ongoing institutional interest and comparisons with competing funds.

The outlook remains positive given the bullish technical setup and strong institutional backing. However, investors face risks from market volatility and fee structure comparisons with competing funds. The divided analyst consensus reflects uncertainty about near-term performance despite the fund's long-term growth trajectory.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Nasdaq100 ETF

The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on QQQ

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN